Strategic Cooperation between GeneQuantum Healthcare and Biocytogen on Development of Antitumor Bioconjugates

Thursday, November 1, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

SUZHOU, China, Oct. 31, 2018 /PRNewswire/ -- GeneQuantum Healthcare and Biocytogen

reached a Strategic Cooperation Agreement focusing on the development of next generation bioconjugates for tumor immunotherapy in Beijing on October 29, 2018. Based on their mutually
beneficial complementary advantages, both companies agreed to integrate GeneQuantum Healthcare's world-class bio-conjugation platform and Biocytogen's tumor immunotherapy antibody drug development and evaluation platform to jointly develop a series novel bioconjugates for tumor immunotherapy and precision medicine.

Dr. Gang Qin from GeneQuantum Healthcare remarked: "GeneQuantum Healthcare has built a diverse and innovative platform in order to face challenges in the biopharmaceutical field. GeneQuantum Healthcare has developed the intelligent ligase-dependent conjugation (iLDC) system based on the independently developed ligase-dependent conjugation (LDC) technology, which provides a systematic solution toward manufacturing next generation bioconjugates. On the other hand, Biocytogen has developed an efficient animal model production platform to screen and develop high-throughput antibody drugs for tumor immuno-oncology. We are excited to collaborate with Biocytogen, a partner that possesses unique features and top-level technologies that are extremely valuable in the process of developing next generation bioconjugates for tumor immunotherapy and targeted therapies to meet the yet unsatisfied clinical demands cancer patients worldwide. We believe this mutual win-win cooperation between these two emerging biotech companies will set a precedent and an example for biomedical intelligent manufacturing in China."

"Through the development of customized gene-edited animal models, Biocytogen can provide clients with high-quality services, including pharmacological efficacy evaluation and R&D of antibody drugs. The unique large-scale in vivo drug efficacy evaluation platform with tailored animal models and the efficient pilot antibody drug discovery process enable Biocytogen to provide pharmaceutical companies with fast and efficient services toward novel antibody drug discovery. Biocytogen is committed to becoming a world-class comprehensive CRO company specialized in biomedical R&D to advance human health. GeneQuantum Healthcare's independent, innovative and world-class intelligent bioconjugate development platform is a leader in the industry," Dr. Yuelei Shen from Biocytogen said. "We hope to harness the integrated advantages of both GeneQuantum Healthcare and Biocytogen to jointly develop new and efficient anti-tumor drugs to satisfy the needs of patients in China and other countries."

About GeneQuantum Healthcare

Founded in Suzhou Industrial Park in 2013, GeneQuantum Healthcare (Suzhou) Co., Ltd. is an innovative hi-tech enterprise focusing on the development of innovative biological drugs and is dedicated toward becoming the leader of Chinese-pioneered biological drugs with international competitive power. The company has established an innovative and world-class platform for the development of intelligent bio-conjugates to satisfy the clinical demands from cancer patients worldwide.

About Biocytogen

Biocytogen, headquartered at Yizhuang/Beijing, has three branches located in Haimen/ Jiangsu, Zhangjiang/Shanghai and Boston, USA. It is a hi-tech biological drug enterprise providing customized animal models, large-scale animal production, and in vivo pharmacological efficacy evaluation based on a robust and efficient gene-editing platform. Biocytogen has established its unique antibody drug R&D service platform through integrating the technologies and resources of its major platforms in order to validate antibody drugs via rapid in vivo screening. Biocytogen's service groups and partners include such top pharmaceutical enterprises as Sanofi, LILLY, Merck, Roche, BMS, Amgen, Hengrui and Beigen as well as such top scientific research institutions and universities as Harvard University, MIT, Stanford University, University of Cambridge, CAS, Peking University and Tsinghua University.

Cision View original content:http://www.prnewswire.com/news-releases/strategic-cooperation-between-genequantum-healthcare-and-biocytogen-on-development-of-antitumor-bioconjugates-300741793.html

SOURCE GeneQuantum



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store